Heart and blood vessel diseases are amongst the worst known complications associated with Type 2 diabetes. People diagnosed with this form of diabetes are prone to high cholesterol and blood fat levels which can cause blood vessels to become clogged.
When the coronary arteries become clogged, the heart muscle itself can become starved for oxygen and various nutrients. When that happens, the heart can slow down or beat with less force, or both. When the heart is unable to pump blood in sufficient quantities to feed the needs of the rest of the body, congestive heart failure develops. Blood that is unable to enter the heart because of congestion, backs up into the lungs which then become congested with fluid.
Exenatide, or Byetta, is a medication that mimics a kind of hormone known as an incretin. It stimulates the pancreas to release more insulin when the food just eaten starts to raise the blood sugar. So, Byetta stimulates insulin secretion when blood sugars have actually risen after your meal, and the insulin secretion should stop when they drop. It also decreases the production of sugar by the liver.
The latest studies on exenatide (Byetta) show that it could also prove a valuable tool in fighting heart disease.
In one such study, published in January 2012 in the journal Diabetologia, investigators at the Karolinska Institutet in Sweden looked at how much blood the hearts of people with Type 2 diabetes were able to pump with and without exenatide. Twenty people with Type 2 diabetes were included in the study...
the hearts of these diabetics were found to be able to pump more blood while they took exenatide (Byetta) than when they took a placebo.this was because their hearts were able to beat faster. Pressure in their lungs was also reduced because the blood was able to flow out of their lungs and into their heart in a timely manner.
It was therefore concluded more study is definitely warranted on the effects of the drug exenatide on the heart.
Britain's National Institute for Health and Clinical Excellence (NICE) published in October 2011 recommendations for the clinical use of Bydureon, a long-acting form of exenatide. The long-acting form of this particular medication must be injected only once. In January 2012 Bydureon was included in NICE's formulary for the National Health Service.
A study called EXSCEL, which includes more than 9000 diabetics, is scheduled to be completed in the year 2017. It aims to discover what use exenatide (Byetta) might have for the prevention and treatment of heart disease.
To discover answers to questions you may be asking yourself about Type 2 Diabetes, click on this link... Natural Diabetes Treatments
Tidak ada komentar:
Posting Komentar